MediciNova, Inc. 2013 Q2 SEC Filing Summary
Business Context and Reporting Period
MediciNova is a development-stage biopharmaceutical company focused on small-molecule therapeutics for serious diseases with unmet medical needs. Its principal programs are MN-166 for neurological disorders and MN-221 for acute exacerbations of asthma and COPD. The Form 10-Q covers the quarter and six months ended June 30, 2013; the interim financial statements are unaudited.
Financial Performance and Position
| Metric | Three Months Ended June 30 | Six Months Ended June 30 |
|---|---|---|
| Revenue | $0.0 million, versus $0.5 million in 2012 | $0.003 million, versus $0.7 million in 2012 |
| Research and development expense | $0.9 million, versus $1.5 million | $1.6 million, versus $3.4 million |
| General and administrative expense | $1.8 million, versus $1.3 million | $3.6 million, versus $3.5 million |
| Operating loss | $2.8 million, versus $2.3 million | $5.2 million, versus $6.2 million |
| Net loss | $2.8 million, or $0.14 per share | $5.2 million, or $0.27 per share |
| Net cash used in operating activities | Not separately reported | $4.7 million, versus $7.3 million |
Revenue consisted primarily of recognition of the $2.5 million non-refundable Kissei upfront payment as related research and development services were performed. Approximately $1.7 million remained deferred at June 30, 2013. Gross margins are not meaningful because no cost of revenues was reported in the current periods and the company remains development-stage.
- Cash and cash equivalents were $12.0 million at June 30, 2013, compared with $4.0 million at December 31, 2012.
- Working capital was $11.4 million. Total assets were $27.7 million and total liabilities were $4.7 million.
- The company reported no debt and no interest expense in 2012 or the first half of 2013. Liabilities included a $2.0 million deferred tax liability and $1.7 million of long-term deferred revenue.
- Net cash provided by financing activities was $12.8 million, primarily from common-stock issuances. Net cash used in investing activities was $39,522.
- Accumulated deficit was $301.4 million at June 30, 2013, including approximately $50.9 million of cumulative non-cash stock-based compensation.
Material Changes Versus the Prior Comparable Period
- Revenue declined to essentially zero because the MN-221 COPD clinical trial that generated Kissei service revenue in 2012 had been completed.
- Research and development expense fell $0.6 million in the quarter and $1.8 million for the six-month period, principally because MN-221 clinical trials ended in 2012. MN-166 spending increased by approximately $0.4 million in the quarter and $0.6 million year to date.
- General and administrative expense increased $0.5 million in the quarter and $0.1 million year to date, primarily due to higher stock-based compensation.
- Cash increased by $8.0 million during the first six months, primarily from equity financing, despite a $4.7 million operating cash burn.
- In May 2013, the company sold 1.16 million common shares and warrants for gross proceeds of approximately $3.7 million, with approximately $3.4 million of net proceeds. The transaction included a related-party purchase by an entity associated with a director.
- By June 30, 2013, the company had sold 1.77 million shares under its Macquarie at-the-market facility for $5.6 million gross and 2.45 million shares under its Aspire facility for $5.3 million gross.
- Common shares outstanding increased to 22.15 million at June 30, 2013 from 17.41 million at December 31, 2012, before considering additional dilution from warrants and options.
Guidance, Outlook, Risks and Unusual Items
- Management expects substantial net losses for the next several years and expects research and development spending on its remaining programs to remain limited except for activities needed to maintain license rights or maximize value.
- Management stated that the June 30, 2013 working capital position was expected to fund operations for at least the next 12 months under the current operating plan, but cautioned that actual cash use could be faster than expected.
- Management expects to continue seeking outside financing. If financing is unavailable, the company may need to delay, reduce or terminate programs, sell programs, or cease operations.
- MN-166 clinical development continued in methamphetamine dependence and opioid addiction. The program received FDA Fast Track designation in February 2013 for methamphetamine dependence. A Phase 1b trial was completed in June 2013, and a grant-supported Phase 2b multiple sclerosis trial was expected to begin enrollment in fall 2013.
- Future MN-221 development was to be designed based on FDA feedback received in October 2012.
- Between July 1 and the filing date, the company received $0.4 million of net proceeds from sales of 165,266 shares under the Macquarie facility. Gross sales under that facility reached its $6.0 million capacity, leaving no remaining availability.
- The former employee litigation was dismissed in arbitration on April 30, 2013, and the company was awarded approximately $100,000 in sanctions. The filing states that no legal proceedings were pending at June 30, 2013.
- Potentially dilutive securities excluded from diluted loss per share totaled approximately 9.4 million shares, consisting of convertible preferred stock, options and warrants.
- The company disclosed no material changes to the risk factors in its 2012 Form 10-K. Key ongoing risks include clinical and regulatory failure, dependence on additional financing, uncertain commercialization prospects, intellectual-property obligations, licensing milestones and potential future litigation.
Important Facts for Investors to Verify
- Verify the cash runway against the continuing operating loss and expected clinical-development spending.
- Assess dilution from the 4.7 million-share increase in common shares, approximately 3.3 million options and approximately 3.9 million warrants outstanding at June 30, 2013.
- Review the status, design, funding and regulatory pathway of MN-166 trials, including the planned multiple sclerosis study.
- Confirm the remaining deferred Kissei revenue and the timing and costs of completing the related services.
- Review the terms and remaining availability of the Aspire financing facility and any subsequent equity financing after the filing date.
- Evaluate whether MN-221 has a viable development plan following the 2012 trial completions and FDA feedback.
- Confirm related-party participation in the May 2013 private placement and the associated warrant terms.